CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Boron Neutron Capture Therapy-Derived Extracellular Vesicles via DNA Accumulation Boost Antitumor Dendritic Cell Vaccine Efficacy.
Boron Neutron Capture Therapy-Derived Extracellular Vesicles via DNA Accumulation Boost Antitumor Dendritic Cell Vaccine Efficacy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
放射肿瘤细胞来源的细胞外囊泡(RT-EVs)除了作为多种肿瘤抗原的整合者外,还包裹着来自受照射肿瘤细胞的大量DNA片段。越来越多的证据表明,这些来自受损细胞的DNA片段参与下游免疫反应,但其中大部分在掺入衍生的RT-EVs之前已在细胞内被降解,因此DNA片段的低丰度限制了RT-EVs的免疫反应。
本研究发现,不同辐射影响RT-EVs中DNA片段的命运。硼中子俘获治疗(BNCT)通过引起更多DNA断裂和DNA氧化以抵抗核酸酶降解,从而诱导RT-EVs(BEVs)中DNA的积累。这归因于10B中子俘获反应产生的α粒子具有高线性能量转移(LET)特性。当被树突状细胞(DCs)内化后,BEVs激活DNA感知通路,导致功能增强,包括抗原呈递、迁移能力和细胞因子分泌。在用BEVs致敏的DCs(BEV@BMDCs)疫苗接种后,效应T细胞显著扩增并浸润到肿瘤中,表明强烈的抗肿瘤免疫激活。BEV@BMDCs不仅有效抑制原发肿瘤生长和转移形成,还引发长期免疫记忆。
总之,提供了一种成功的DC疫苗,作为肿瘤疫苗的有前景候选者。
Radiated tumor cell-derived extracellular vesicles (RT-EVs) encapsulate abundant DNA fragments from irradiated tumor cells, in addition to acting as integrators of multiple tumor antigens. Accumulating evidence indicates these DNA fragments from damaged cells are involved in downstream immune responses, but most of them are degraded in cells before incorporation into derived RT-EVs, thus the low abundance of DNA fragments limits immune responses of RT-EVs.
Here, this study found that different radiations affected fates of DNA fragments in RT-EVs. Boron neutron capture therapy (BNCT) induced DNA accumulation in RT-EVs (BEVs) by causing more DNA breaks and DNA oxidation resisting nuclease degradation. This is attributed to the high-linear energy transfer (LET) properties of alpha particles from the neutron capture reaction of 10 B.
When being internalized by dendritic cells (DCs), BEVs activated the DNA sensing pathway, resulting in functional enhancements including antigen presentation, migration capacity, and cytokine secretion. After vaccination of the BEVs-educated DCs (BEV@BMDCs), the effector T cells significantly expanded and infiltrated into tumors, suggesting robust anti-tumor immune activation. BEV@BMDCs not only effectively inhibited the primary tumor growth and metastasis formation but also elicited long-term immune memory.
In conclusion, a successful DC vaccine is provided as a promising candidate for tumor vaccine.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。